Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 2/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 3/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL898173 | 0.72 | CYP1A2 (0.41) | KDM4ESMN1; SMN2 | |
| SCHEMBL24262442 | 0.72 | YTHDC1 (0.39) | BCL2MCL1SMN1; SMN2 | |
| SCHEMBL15136219 | 0.70 | EGFR (0.31) | — | |
| SCHEMBL15136217 | 0.70 | EGFR (0.31) | — | |
| SCHEMBL463190 | 0.69 | CDC7 (0.39) | HPGD | |
| SCHEMBL10959517 | 0.65 | EGFR (0.48) | KDM4ENPC1HPGDRAB9A | |
| SCHEMBL10956328 | 0.64 | EGFR (0.56) | TP53NPC1HPGDRAB9A | |
| SCHEMBL19957830 | 0.64 | CRHR1 (0.36) | PDE1BPDE1APDE1CCRHR1SMN1; SMN2 | |
| SCHEMBL10958191 | 0.62 | EGFR (0.46) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10956544 | 0.62 | RXRA (0.50) | TP53CRHR1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621903-B1 | N-HETEROARYL COMPOUNDS | INTERVET INT BV (NL) | 2017-03-01 | — | — | EP | disclosed |
| US-8877934-B2 | N-heteroaryl compounds | INTERVET INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2621903-A1 | N-HETEROARYL COMPOUNDS | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | INTERVET INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2012041873-A1 | N-HETEROARYL COMPOUNDS | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196993-A1 | N-HETEROARYL COMPOUNDS | HNMT, SQLE, PIGO | PDE1B 3909/4885PDE1A 4252/4885PDE1C 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.